https://www.selleckchem.com/products/OSI-906.html
003). No significant results were found by dividing the cohort using the positivity to anti-CCP and/or RF. CONCLUSIONS Earlier onset and a longer disease duration in anti-CarP positive patients might suggest they are specific risk factors for RA in this subgroup of patients. The correlation between the anti-CarP positivity at baseline and the reduction of disease activity during the first six months of treatment with abatacept allowed us to hypothesise that anti-CarP antibodies, but not anti-CCP and/or RF, could be used as a good clinic
Like
Comment
Share
